glp 1 comorbidities GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Dual GIP/GLP-1 receptor agonists: New

Nat Reviews Disease Primers

Next, we identified those patients with at least one 24-hour urine collection before initiation of GLP and at least one 24-hour urine collection while still on GLP

Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists

Mochi for transparent pricing

Our providers bring extensive experience in medical weight loss, honest assessment of candidacy and expectations, ongoing monitoring and dosing adjustments, and immediate support if concerns arise